hCG

Evidence & Status

• FDA Approved
• Strong Human Evidence
• Established

At a Glance

A placental hormone represented through distinct prescription hCG products used in product-specific reproductive care; it is not an approved weight-loss therapy.

Plain English

hCG products are used in particular fertility settings under specialist supervision. A product label does not support broad claims about weight loss or unsupervised hormonal use.

Overview

Human chorionic gonadotropin is an endogenous placental glycoprotein hormone. Ovidrel (recombinant choriogonadotropin alfa) and Novarel (chorionic gonadotropin) are distinct prescription products; their routes, dose units, indications, contraindications, and warnings must not be interchanged. This record does not support hCG for weight loss or represent off-label testosterone-replacement adjunct use as an approved indication.

Research Summary

The cited sources establish the separated Ovidrel and Novarel product contexts and the FDA boundary that hCG is not an approved weight-loss treatment. This record does not make a comparative claim between products or an efficacy claim for off-label testosterone-replacement adjunct use.

Research Areas

• Female infertility
• Reproductive endocrinology
• Product-specific fertility care

Safety & Risks

Serious Risks

• Ovarian hyperstimulation syndrome can be serious or life-threatening in women receiving ovulation-induction treatment.
• Multiple gestation and thromboembolic complications are described risks in assisted-reproduction contexts.
• hCG products are not FDA-approved for weight loss.

Legal Status by Region

United States

Ovidrel and Novarel are distinct FDA-labeled prescription products with product-specific reproductive indications. FDA does not approve hCG products for weight loss.

United Kingdom

Not assessed in this record.

Australia

Not assessed in this record.

Canada

Not assessed in this record.